As of Jun 27, 2018 Viking Therapeutics Inc (NASDAQ:VKTX) Shorts Reduced By 0.3%

June 27, 2018 - By Rebecca Betts

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

Viking Therapeutics Inc (NASDAQ:VKTX) showed a decrease of 0.3% in shorted shares. In June was announced VKTX’s total 2.91M shorted shares by FINRA. The 2.92M previous shares are down with 0.3%. Viking Therapeutics Inc (NASDAQ:VKTX) has 892,100 shares average volume. It’ll cost 3 days for VKTX to restore its previous position. Viking Therapeutics Inc float short is 15.78%.

Ticker’s shares touched $10.35 during the last trading session after 0.58% change.Viking Therapeutics, Inc. has volume of 1.30 million shares. Since June 27, 2017 VKTX has risen 320.16% and is uptrending. VKTX outperformed the S&P 500 by 307.59%.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The firm is worth $616.43 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Last it reported negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

In total 4 analysts cover Viking Therapeutics (NASDAQ:VKTX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:VKTX)’s analyst reports since March 8, 2018 according to StockzIntelligence Inc. On Friday, June 1 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, March 8 the rating was maintained by Roth Capital with “Buy”. On Friday, June 1 the rating was maintained by Maxim Group with “Buy”. On Monday, March 26 the stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by H.C. Wainwright.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news published recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Fool.com or Fool.com. The titles are as follows: “Viking Therapeutics: Hallmark Moment” published on June 13, 2018, “Viking Therapeutics: What Now After ‘Yuge’ Rally?” on June 12, 2018, “Viking Therapeutics: Sell The Pop On The Sympathy Play” with a publish date: June 01, 2018, “3 Growth Stocks at Deep-Value Prices” and the last “Why Viking Therapeutics Stock Is On Fire Today” with publication date: May 31, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: